New Fall Vaccine Rules Every Adult Over 65 Should Know

On September 2, 2026, four of the country's most influential medical organizations — the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the Infectious Diseases Society of America (IDSA) — published coordinated fall vaccine recommendations for adults over 65 that break new ground. The most significant change: if you're 65 or older, one COVID-19 shot this season is no longer enough. The guidance recommends a second dose six months after the first. That's a meaningful shift, and it didn't happen in a vacuum.

Why Four Medical Societies Stepped In

Here's the unusual backdrop: the CDC has not yet issued updated COVID-19 or RSV recommendations for the 2026–2027 respiratory season. That left clinicians and patients without official federal guidance heading into fall — and these four societies decided not to wait.

Their recommendations weren't made on instinct. They were informed by three systematic evidence reviews published in JAMA, giving the guidance a rigorous scientific foundation even without CDC backing. The societies coordinated their release deliberately, presenting a unified front rather than competing voices. That kind of cross-society alignment is rare, and it signals how seriously these organizations are treating this season's respiratory risks.

For adults 50 and older, the timing matters. Respiratory illnesses — flu, COVID-19, and RSV — hit this age group harder than any other. Hospitalizations climb steeply after 65, and recovery takes longer. Getting the right vaccines, at the right time, is one of the most effective things you can do before November arrives.

The New Two-Dose COVID Rule for Adults 65 and Older

This is the headline change. Under the new AAFP-coordinated guidance, all adults 19 and up should receive an annual COVID-19 vaccine. But if you're 65 or older — or immunocompromised at any age — the recommendation goes further: get a second COVID-19 dose approximately six months after your first.

Why two doses? Immune response weakens with age, a well-documented phenomenon called immunosenescence. A single vaccine dose may produce a robust initial response, but protection can wane faster in older adults than in younger people. The six-month interval is designed to refresh that protection right as respiratory season peaks in late fall and winter.

If you got your first updated COVID-19 shot in early fall — say, October — your second dose would fall around April. That's worth writing down now, because a six-month gap is easy to lose track of, especially if you're managing multiple health appointments. SteadiDay's free Trusted Contacts feature can help here: you can loop in a family member or close friend who gets notified when you've logged a health activity, making it easier to stay accountable across a season that spans two calendar years.

The immunocompromised designation also deserves attention. If you're on immunosuppressive medications, have certain cancers, or have had an organ transplant, talk to your doctor about whether you qualify for this two-dose protocol regardless of age.

RSV Guidance Gets More Specific — and More Inclusive

RSV used to be thought of primarily as a children's illness. That understanding has shifted dramatically. Adults 65 and older account for the vast majority of RSV-related hospitalizations and deaths in the U.S. each year, and the new guidance reflects that reality with age-specific recommendations.

For adults 75 and older, RSV vaccination is now universally recommended — no additional risk factors required. For adults between 50 and 74, the guidance recommends vaccination for those at elevated risk, which includes people with chronic lung disease, heart disease, diabetes, obesity, or living in a long-term care facility.

If you're in the 50–74 range and unsure whether you qualify as "elevated risk," the honest answer is: probably check with your doctor, but don't dismiss it. Chronic conditions that feel well-managed can still leave your immune system less equipped to fight off a serious RSV infection. The downside of getting vaccinated is minimal. The downside of a preventable RSV hospitalization is not.

Video: Doctors fill CDC guidance void with new vaccine recommendations -- NBC News

The First mRNA Flu Vaccine Is Now Available for Adults 50 and Older

Separate from the medical society guidance — but landing just weeks before it — the FDA approved Moderna's mFLUSIVA on August 5, 2026. It's the first mRNA-based influenza vaccine ever approved, and it's authorized specifically for adults 50 and older.

According to Harvard Health's coverage of the approval, clinical trials showed mFLUSIVA outperformed traditional flu shots in preventing infection. That's a notable finding. Traditional flu vaccines have long been effective at reducing severe illness and hospitalization — but their effectiveness at preventing infection outright has been more variable. An mRNA approach, which can be updated faster and may produce a stronger immune response, represents a real advancement for this age group.

A JAMA systematic review of influenza vaccine effectiveness for the 2026–2027 season confirmed that flu vaccines continue to reduce risk of severe disease and hospitalization in older adults, with no new safety concerns identified. That review also helped inform the broader medical society recommendations released in September.

mFLUSIVA won't immediately replace every option at every pharmacy — new vaccines roll out gradually. But if it's available where you get your shots, it's worth asking about. Your doctor or pharmacist can tell you whether it's the right fit for you, particularly if you've had concerns about flu vaccine effectiveness in past seasons.

What the Evidence Actually Says About These Vaccines

Vaccine skepticism tends to increase with age, ironically at exactly the time when the stakes are highest. So it's worth being direct about what the research shows.

The JAMA evidence reviews that underpinned these recommendations are systematic reviews — the gold standard of medical evidence, pooling data across multiple high-quality studies rather than relying on any single trial. They found consistent benefit across all three vaccine categories (influenza, COVID-19, and RSV) for older adults, with the risk-benefit calculation tilting heavily toward vaccination.

RSV vaccines, for example, have shown strong efficacy in adults over 60 in clinical trials — reducing RSV-associated lower respiratory tract disease by more than 80% in some studies. COVID-19 booster doses in adults 65 and older have been associated with meaningful reductions in hospitalizations and death during periods of active variant circulation. Flu vaccines, even in years of imperfect strain matching, consistently reduce the severity of illness when infection does occur.

None of these vaccines prevent every infection. That's not what they're designed to do. They're designed to keep infections from becoming hospitalizations — and for adults over 65, that distinction matters enormously.

What to Do Before Respiratory Season Peaks

The practical checklist is shorter than it might feel. Here's how to approach this season:

Schedule your flu shot for early-to-mid October. That's the sweet spot — early enough to build immunity before peak season, late enough that protection doesn't wane by February. Ask your pharmacist whether mFLUSIVA is available at your location.

Get your annual COVID-19 vaccine if you haven't already. If you're 65 or older, mark your calendar for a second dose six months later. Put it in your phone. Tell someone who'll remind you.

Ask your doctor about RSV. If you're 75 or older, the recommendation is universal. If you're 50–74, run through your health history with your provider — the conversation takes five minutes and could save you a very difficult few weeks in January.

Don't try to manage this alone. SteadiDay's free Trusted Contacts feature lets you share health milestones — including vaccination check-ins — with people who care about you. It's a small thing that makes staying on top of a multi-month vaccination schedule much easier, especially when life gets busy.

The medical societies that released this guidance didn't do so to be alarmist. They did it because the evidence supports action, and because adults 50 and older deserve clear, current information — even when federal agencies haven't caught up yet.

Common Questions

Do adults 65 and older really need two COVID-19 vaccine doses this season?

Yes, according to the 2026–2027 guidance coordinated by AAFP, AAP, ACOG, and IDSA. Adults 65 and older — and immunocompromised individuals of any age — are now recommended to receive a second COVID-19 dose approximately six months after their first. The reasoning is that immune protection wanes faster in older adults, and a second dose helps maintain coverage through the full respiratory season.

Who should get the RSV vaccine in 2026–2027?

The new guidance recommends RSV vaccination universally for all adults 75 and older, regardless of health status. For adults between 50 and 74, vaccination is recommended for those at elevated risk — including people with chronic lung disease, heart disease, diabetes, obesity, or those living in long-term care facilities. If you're unsure whether you qualify, your primary care doctor can help assess your risk.

What is mFLUSIVA, and is it better than a regular flu shot?

mFLUSIVA is the first mRNA-based influenza vaccine, approved by the FDA on August 5, 2026, for adults 50 and older. Clinical trials showed it outperformed traditional flu shots in preventing infection — not just severe disease. It's a new option, not yet universally available at every pharmacy, so it's worth asking your pharmacist or doctor whether it's offered at your location this season.

Why did medical societies issue vaccine guidance instead of the CDC?

As of September 2026, the CDC had not yet released updated COVID-19 or RSV recommendations for the 2026–2027 respiratory season. To fill that gap, four major medical organizations — AAFP, AAP, ACOG, and IDSA — coordinated their own evidence-based guidance, informed by systematic reviews published in JAMA. The recommendations carry significant clinical weight even without CDC endorsement.